Among the multiple approaches blocking c‐Myc oncogenic activity, PLK1 inhibition by selective compounds, such as BI 2536 and BI 6727 (Volarsetib), represents an attractive therapeutic strategy in the treatment of c‐Myc‐driven tumours.18, 19. This evidence concerns the gene MYC and neoplasm.